{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T13:01:44Z","timestamp":1648904504350},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2010,10,9]],"date-time":"2010-10-09T00:00:00Z","timestamp":1286582400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s12032-010-9708-8","type":"journal-article","created":{"date-parts":[[2010,10,13]],"date-time":"2010-10-13T18:42:23Z","timestamp":1286995343000},"page":"246-249","source":"Crossref","is-referenced-by-count":0,"title":["Impressive efficacy of sorafenib in a patient with an hepatocellular carcinoma and a portal vein thrombosis associated with a metastatic ENT cancer"],"prefix":"10.1007","volume":"28","author":[{"given":"Catherine","family":"Leroux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elodie","family":"Vaul\u00e9on","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Pracht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmina","family":"Zoheir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eveline","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Odile","family":"Audrain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Luc","family":"Raoul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,10,9]]},"reference":[{"key":"9708_CR1","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djn134","volume":"100","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698\u2013711.","journal-title":"J Natl Cancer Inst"},{"key":"9708_CR2","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"9708_CR3","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1007\/s10620-007-9808-2","volume":"52","author":"D Takizawa","year":"2007","unstructured":"Takizawa D, Kakizaki S, Sohara N, Sato K, Takagi H, Arai H, et al. Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis. Dig Dis Sci. 2007;52:3290\u20135.","journal-title":"Dig Dis Sci"},{"key":"9708_CR4","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/ajg.2009.140","volume":"104","author":"M Novi","year":"2009","unstructured":"Novi M, Lauritano EC, Piscaglia AC, Barbaro B, Zocco MA, Pompili M, et al. Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma. Am J Gastroenterol. 2009;104:1852\u20134.","journal-title":"Am J Gastroenterol"},{"key":"9708_CR5","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.clon.2008.05.004","volume":"20","author":"SS Wu","year":"2008","unstructured":"Wu SS, Yen HH, Chung CY. Oesophageal variceal bleeding in hepatocellular carcinoma with portal vein thrombosis: improved outcome in response to molecular target therapy. Clin Oncol (R Coll Radiol). 2008;20:566\u20137.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"9708_CR6","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","volume":"354","author":"JA Bonner","year":"2006","unstructured":"Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567\u201378.","journal-title":"N Engl J Med"},{"key":"9708_CR7","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116\u201327.","journal-title":"N Engl J Med"},{"key":"9708_CR8","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/hed.20326","volume":"28","author":"P Lothaire","year":"2006","unstructured":"Lothaire P, de Azambuja E, Dequanter D, Lalami Y, Sotiriou C, Andry G, et al. Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck. 2006;28:256\u201369.","journal-title":"Head Neck"},{"key":"9708_CR9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.0959-9673.2005.00447.x","volume":"86","author":"GR Thomas","year":"2005","unstructured":"Thomas GR, Nadiminti H, Regalado J. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol. 2005;86:347\u201363.","journal-title":"Int J Exp Pathol"},{"key":"9708_CR10","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2006.10.2871","volume":"25","author":"C Elser","year":"2007","unstructured":"Elser C, Siu LL, Winquist E, Agulnik M, Pond GR, Chin SF, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol. 2007;25:3766\u201373.","journal-title":"J Clin Oncol"},{"key":"9708_CR11","doi-asserted-by":"crossref","unstructured":"Williamson SK, Moon J, Huang CH, Guaglianone P, Wolf GT, Urba SG. A phase II trial of Sorafenib in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma (HNSCC). A Southwest Oncology Group (SWOG) trial. J Clin Oncol (Meeting Abstracts) 2007;25:6044.","DOI":"10.1200\/jco.2007.25.18_suppl.6044"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9708-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-010-9708-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9708-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T21:33:49Z","timestamp":1591997629000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-010-9708-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,9]]},"references-count":11,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["9708"],"URL":"https:\/\/doi.org\/10.1007\/s12032-010-9708-8","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,9]]}}}